EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
Saved in:
| Published in: | Obesity facts Vol. 9; no. 2; pp. 65 - 90 |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
Basel, Switzerland
S. Karger GmbH
2016
Karger Publishers |
| Subjects: | |
| ISSN: | 1662-4025, 1662-4033 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Author_xml | – sequence: 1 email: easloffice@easloffice.eu – sequence: 2 – sequence: 3 |
|---|---|
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27055256$$D View this record in MEDLINE/PubMed |
| BookMark | eNptks1v0zAUwC00xD7gwB0hS1zgEOavOMkFqerWbVKhSMDZenZeWo80LnY6af89ydpVDO3ybD3__Ht-tk_JURc6JOQtZ585z6tzxphSUir1gpxwrUWmmJRHh7nIj8lpSreMaa4K_ooci4Llucj1CXGXkx_zbAgXY1jQaes776Cl3yO43jukV1tf45DFRJsQab9C-hU6WOIau56Ghn4LXTZpXViF1js6g76_p3N_h5Fe-ISQ8DV52UCb8M1-PCO_Zpc_p9fZfHF1M53MMzecSmVONI6htlKVArHMrW6KxkqBeS0LXXGuKyWYgBorq2WjrCsGlAteWlG6opFn5GbnrQPcmk30a4j3JoA3D4kQlwbi0FOLBgqrrOalrIErLtFax2slbV0B5GhhcH3ZuTZbu8baDb1GaJ9In650fmWW4c7kWqmiqgbBx70ghj9bTL1Z--SwbaHDsE2GF6WsBFN8RN__W-tQ5PGVBuB8B7gYUorYGOd76H0YS_vWcGbGf2AO_2DY8em_HY_S59gPO_Y3xCXGA7mYTXaE2dTj5b57ltpL_gKdMsVk |
| CitedBy_id | crossref_primary_10_1016_j_bpsgos_2025_100488 crossref_primary_10_1111_liv_15917 crossref_primary_10_1016_j_phrs_2024_107245 crossref_primary_10_3390_medicines5020047 crossref_primary_10_3390_jcm13164738 crossref_primary_10_3390_nu15183987 crossref_primary_10_1007_s13340_020_00453_7 crossref_primary_10_1186_s12876_024_03160_8 crossref_primary_10_1038_s41430_022_01081_x crossref_primary_10_1016_j_jhep_2020_03_036 crossref_primary_10_3389_fcvm_2023_1172178 crossref_primary_10_1007_s00268_022_06781_w crossref_primary_10_1002_VIW_20240010 crossref_primary_10_1186_s12967_021_03210_9 crossref_primary_10_1080_10520295_2018_1517898 crossref_primary_10_1016_j_cgh_2021_05_052 crossref_primary_10_3390_nu15082005 crossref_primary_10_3389_fphar_2022_924021 crossref_primary_10_1016_j_cca_2025_120156 crossref_primary_10_1016_j_nutres_2023_09_005 crossref_primary_10_1371_journal_pone_0254892 crossref_primary_10_1002_fft2_535 crossref_primary_10_3390_jpm13060932 crossref_primary_10_22207_JPAM_15_4_75 crossref_primary_10_1371_journal_pone_0273171 crossref_primary_10_1016_j_jhep_2020_06_016 crossref_primary_10_1007_s00394_022_02934_8 crossref_primary_10_1007_s13679_019_00345_1 crossref_primary_10_3390_jcm12113741 crossref_primary_10_1007_s00261_025_04909_9 crossref_primary_10_57264_cer_2024_0096 crossref_primary_10_1007_s11938_020_00318_7 crossref_primary_10_1111_liv_16220 crossref_primary_10_3389_fnut_2022_1002669 crossref_primary_10_1080_07853890_2021_1943514 crossref_primary_10_1007_s12020_016_1112_5 crossref_primary_10_1016_j_numecd_2024_10_007 crossref_primary_10_1097_LVT_0000000000000544 crossref_primary_10_1097_MEG_0000000000002456 crossref_primary_10_3389_fmed_2022_1024836 crossref_primary_10_3390_nu17172905 crossref_primary_10_5812_hepatmon_92992 crossref_primary_10_1159_000518407 crossref_primary_10_1136_bmjopen_2023_074432 crossref_primary_10_2147_HMER_S265631 crossref_primary_10_3390_ijms17050633 crossref_primary_10_1002_fsn3_3549 crossref_primary_10_1089_met_2020_0099 crossref_primary_10_1016_j_aohep_2023_101085 crossref_primary_10_1016_j_obmed_2022_100455 crossref_primary_10_1016_j_jhepr_2024_101267 crossref_primary_10_1186_s12887_024_05263_3 crossref_primary_10_1007_s40519_017_0393_x crossref_primary_10_1093_nutrit_nuz029 crossref_primary_10_3390_antiox9090808 crossref_primary_10_1016_j_gastre_2018_05_013 crossref_primary_10_1097_HEP_0000000000000356 crossref_primary_10_1155_2023_5521239 crossref_primary_10_3389_fmed_2023_1124275 crossref_primary_10_7759_cureus_43635 crossref_primary_10_1002_ncp_10917 crossref_primary_10_3390_nu12072151 crossref_primary_10_5812_hepatmon_135941 crossref_primary_10_1007_s12072_025_10782_x crossref_primary_10_1111_jgh_14607 crossref_primary_10_1177_20406223221122478 crossref_primary_10_7759_cureus_23435 crossref_primary_10_1016_j_gastrohep_2022_02_005 crossref_primary_10_1016_j_metabol_2021_154770 crossref_primary_10_1155_2023_6492478 crossref_primary_10_1016_j_jceh_2020_11_004 crossref_primary_10_1016_j_jdiacomp_2023_108405 crossref_primary_10_1097_HC9_0000000000000451 crossref_primary_10_1111_jgh_14150 crossref_primary_10_1016_j_dld_2018_03_029 crossref_primary_10_1161_HYPERTENSIONAHA_119_13419 crossref_primary_10_1371_journal_pone_0201308 crossref_primary_10_1016_j_metabol_2022_155248 crossref_primary_10_1007_s11886_024_02181_9 crossref_primary_10_1038_s41366_021_00856_9 crossref_primary_10_3389_fmed_2023_1294425 crossref_primary_10_1016_j_ejim_2022_03_025 crossref_primary_10_1186_s12876_021_02038_3 crossref_primary_10_1038_s41598_023_31686_6 crossref_primary_10_1016_j_clinre_2023_102279 crossref_primary_10_2147_JMDH_S525751 crossref_primary_10_1007_s00394_021_02521_3 crossref_primary_10_1016_j_aohep_2024_101485 crossref_primary_10_1016_j_metabol_2022_155370 crossref_primary_10_1017_S1368980021001762 crossref_primary_10_1016_j_metabol_2023_155694 crossref_primary_10_3390_nu14071500 crossref_primary_10_1007_s12072_022_10469_7 crossref_primary_10_1155_2022_3465980 crossref_primary_10_3390_nu12082178 crossref_primary_10_3390_nu16142254 crossref_primary_10_1155_2022_6799414 crossref_primary_10_1186_s12906_017_1707_2 crossref_primary_10_1007_s00261_020_02684_3 crossref_primary_10_3390_biomedicines10010182 crossref_primary_10_1186_s12944_024_02220_y crossref_primary_10_1016_j_ejrad_2024_111552 crossref_primary_10_2147_DMSO_S342505 crossref_primary_10_4254_wjh_v13_i11_1584 crossref_primary_10_1007_s12020_023_03312_y crossref_primary_10_1016_j_advnut_2023_01_001 crossref_primary_10_1016_j_ando_2020_05_003 crossref_primary_10_1136_gutjnl_2021_324243 crossref_primary_10_3390_microorganisms8101526 crossref_primary_10_3390_foods10123126 crossref_primary_10_1097_MEG_0000000000001319 crossref_primary_10_1021_acs_jmedchem_5c00919 crossref_primary_10_34172_hpp_2023_10 crossref_primary_10_1007_s40200_023_01293_3 crossref_primary_10_1038_s41598_021_03583_3 crossref_primary_10_1111_liv_16019 crossref_primary_10_1111_hepr_14019 crossref_primary_10_1007_s11901_017_0374_6 crossref_primary_10_13048_jkm_25016 crossref_primary_10_3389_fphar_2022_905126 crossref_primary_10_1093_nutrit_nuac092 crossref_primary_10_1016_j_biopha_2018_12_003 crossref_primary_10_1186_s40001_022_00731_x crossref_primary_10_3390_ijms23052764 crossref_primary_10_1111_eci_13731 crossref_primary_10_4254_wjh_v13_i7_790 crossref_primary_10_1186_s13063_020_04362_7 crossref_primary_10_1016_j_rbmo_2025_104872 crossref_primary_10_1080_08998280_2024_2372753 crossref_primary_10_3389_fcvm_2024_1338156 crossref_primary_10_7759_cureus_63445 crossref_primary_10_1016_j_cgh_2020_01_020 crossref_primary_10_3390_ijms24065295 crossref_primary_10_1038_s41430_020_0679_3 crossref_primary_10_1097_TP_0000000000002361 crossref_primary_10_1111_liv_16224 crossref_primary_10_3390_nu17101618 crossref_primary_10_1016_j_phrs_2020_104799 crossref_primary_10_1111_liv_15264 crossref_primary_10_2174_1381612826666201102104902 crossref_primary_10_3390_diseases12080180 crossref_primary_10_1016_S2468_1253_21_00132_1 crossref_primary_10_1080_03602532_2017_1293683 crossref_primary_10_3389_fnut_2023_1062008 crossref_primary_10_1177_0022034519866442 crossref_primary_10_3389_fendo_2025_1521168 crossref_primary_10_3390_ijerph15112521 crossref_primary_10_3389_fmed_2023_1034626 crossref_primary_10_1016_j_ultrasmedbio_2022_03_019 crossref_primary_10_1016_j_lfs_2023_121943 crossref_primary_10_3390_ijms25063092 crossref_primary_10_3748_wjg_v25_i8_888 crossref_primary_10_1089_met_2022_0105 crossref_primary_10_1007_s12072_020_10094_2 crossref_primary_10_1155_2019_2151302 crossref_primary_10_1016_j_soard_2017_07_032 crossref_primary_10_3389_fped_2019_00491 crossref_primary_10_1002_ueg2_12389 crossref_primary_10_1016_j_heliyon_2023_e16401 crossref_primary_10_1111_nbu_12707 crossref_primary_10_18621_eurj_1631079 crossref_primary_10_3748_wjg_v22_i27_6318 crossref_primary_10_1097_MD_0000000000035804 crossref_primary_10_7717_peerj_17810 crossref_primary_10_1007_s10620_023_08059_0 crossref_primary_10_1111_liv_14548 crossref_primary_10_1016_j_jocn_2025_111251 crossref_primary_10_1016_j_gastrohep_2017_12_003 crossref_primary_10_1016_j_jhep_2024_05_042 crossref_primary_10_1038_s41598_024_80895_0 crossref_primary_10_1111_cen_14062 crossref_primary_10_1017_S0029665119000569 crossref_primary_10_1111_hepr_14054 crossref_primary_10_1159_000497461 crossref_primary_10_14366_usg_23194 crossref_primary_10_3390_metabo13070850 crossref_primary_10_1038_s12276_023_01102_0 crossref_primary_10_1001_jamanetworkopen_2021_23923 crossref_primary_10_4093_dmj_2019_0042 crossref_primary_10_3389_fnut_2024_1371137 crossref_primary_10_1002_poh2_89 crossref_primary_10_1016_j_clinre_2025_102649 crossref_primary_10_1111_liv_15404 crossref_primary_10_1016_j_clnu_2023_08_001 crossref_primary_10_1177_20420188221145549 crossref_primary_10_3390_jcm10132910 crossref_primary_10_1038_s41392_022_01178_6 crossref_primary_10_3390_metabo12100954 crossref_primary_10_1016_j_amjms_2024_06_022 crossref_primary_10_3748_wjg_v24_i30_3330 crossref_primary_10_1159_000529814 crossref_primary_10_1186_s13063_024_08208_4 crossref_primary_10_1210_clinem_dgaa575 crossref_primary_10_1111_apt_70376 crossref_primary_10_1097_NNE_0000000000001050 crossref_primary_10_1080_1120009X_2023_2246786 crossref_primary_10_3389_fphar_2022_863839 crossref_primary_10_3390_ijms221910604 crossref_primary_10_3390_biomedicines9101346 crossref_primary_10_1016_j_gtc_2019_09_003 crossref_primary_10_1186_s43066_025_00442_y crossref_primary_10_3389_fonc_2023_1203791 crossref_primary_10_3390_ijms222011128 crossref_primary_10_1016_j_jlr_2025_100818 crossref_primary_10_1097_MEG_0000000000002711 crossref_primary_10_2196_57168 crossref_primary_10_1111_liv_15188 crossref_primary_10_1097_MD_0000000000021898 crossref_primary_10_1080_00365521_2019_1644367 crossref_primary_10_1016_j_jhep_2020_04_026 crossref_primary_10_3350_cmh_2021_0406 crossref_primary_10_1007_s00292_020_00800_0 crossref_primary_10_1111_jvh_13796 crossref_primary_10_3390_nu12030825 crossref_primary_10_1017_S0007114521001100 crossref_primary_10_1136_bmjpo_2024_003138 crossref_primary_10_1016_j_clinimag_2024_110097 crossref_primary_10_1080_07853890_2023_2264850 crossref_primary_10_1016_j_jhep_2020_04_006 crossref_primary_10_1186_s12876_025_03921_z crossref_primary_10_3390_antiox11010069 crossref_primary_10_1111_eci_13648 crossref_primary_10_1111_hepr_13502 crossref_primary_10_1002_osp4_637 crossref_primary_10_1016_j_clnesp_2024_11_032 crossref_primary_10_1093_ofid_ofac279 crossref_primary_10_3390_metabo15030149 crossref_primary_10_1038_s41598_021_99958_7 crossref_primary_10_1016_j_gastre_2022_02_004 crossref_primary_10_1080_07853890_2024_2337739 crossref_primary_10_1111_apt_17931 crossref_primary_10_1002_ueg2_12508 crossref_primary_10_1111_apt_17257 crossref_primary_10_1111_hepr_13737 crossref_primary_10_1111_jvh_13568 crossref_primary_10_1080_17460441_2020_1811674 crossref_primary_10_1016_j_gastrohep_2022_04_001 crossref_primary_10_1055_a_1491_1771 crossref_primary_10_3390_nu14173533 crossref_primary_10_1016_j_obmed_2020_100278 crossref_primary_10_3390_nu11061386 crossref_primary_10_3390_jcm9010259 crossref_primary_10_1016_j_nurpra_2022_10_012 crossref_primary_10_1002_edm2_456 crossref_primary_10_1016_j_acra_2025_02_013 crossref_primary_10_1097_JS9_0000000000001387 crossref_primary_10_1097_MD_0000000000032734 crossref_primary_10_2147_JIR_S466469 crossref_primary_10_3390_livers5010011 crossref_primary_10_3727_105221617X15124844266408 crossref_primary_10_1002_cld_1229 crossref_primary_10_1111_dme_15317 crossref_primary_10_4103_ijpvm_IJPVM_274_19 crossref_primary_10_1016_j_gastre_2022_04_010 crossref_primary_10_1155_2019_8742075 crossref_primary_10_1080_15257770_2024_2310044 crossref_primary_10_3390_jcm10112415 crossref_primary_10_1007_s10620_023_08031_y crossref_primary_10_1016_j_jhep_2023_02_033 crossref_primary_10_1097_SGA_0000000000000443 crossref_primary_10_1186_s12986_023_00733_4 crossref_primary_10_1109_JTEHM_2020_3001488 crossref_primary_10_1016_j_gene_2025_149466 crossref_primary_10_1007_s12010_021_03486_z crossref_primary_10_2196_14802 crossref_primary_10_3390_plants11243585 crossref_primary_10_4103_abr_abr_354_21 crossref_primary_10_1080_17474124_2022_2016391 crossref_primary_10_1111_hepr_14097 crossref_primary_10_1002_jum_16048 crossref_primary_10_1007_s12602_024_10365_6 crossref_primary_10_3390_foods10102242 crossref_primary_10_1002_jgh3_70155 crossref_primary_10_1259_bjr_20170436 crossref_primary_10_1002_jum_15070 crossref_primary_10_1016_j_clinre_2020_08_006 crossref_primary_10_1016_j_scispo_2020_01_006 crossref_primary_10_1038_s41440_024_01708_5 crossref_primary_10_3390_biomedicines11020586 crossref_primary_10_3389_fmed_2024_1425145 crossref_primary_10_3390_ijms20030752 crossref_primary_10_1111_dom_15733 crossref_primary_10_1038_s42003_022_04237_4 crossref_primary_10_26693_jmbs04_04_064 crossref_primary_10_29254_2077_4214_2022_3_166_160_164 crossref_primary_10_3390_ijerph20010667 crossref_primary_10_3390_diseases6030083 crossref_primary_10_1016_j_acra_2024_09_002 crossref_primary_10_1007_s13679_023_00519_y crossref_primary_10_3390_healthcare10020374 crossref_primary_10_1016_j_iliver_2022_09_001 crossref_primary_10_1016_j_sjbs_2018_12_016 crossref_primary_10_1080_15502783_2023_2217783 crossref_primary_10_1177_03000605231204462 crossref_primary_10_3390_medicina60081278 crossref_primary_10_1136_bmjopen_2021_049767 crossref_primary_10_1038_s41598_022_27353_x crossref_primary_10_1007_s42000_024_00588_1 crossref_primary_10_1080_13813455_2021_1890128 crossref_primary_10_3350_cmh_2022_0367 crossref_primary_10_1002_phar_2489 crossref_primary_10_3390_medicina57080822 crossref_primary_10_1016_j_rgmxen_2021_09_002 crossref_primary_10_1016_j_ultrasmedbio_2025_06_011 crossref_primary_10_3390_v15081730 crossref_primary_10_1038_s41598_022_16788_x crossref_primary_10_1111_liv_16078 crossref_primary_10_1055_a_2255_7246 crossref_primary_10_7759_cureus_44413 crossref_primary_10_3390_ijerph17145217 crossref_primary_10_3390_biomedicines13020359 crossref_primary_10_3389_ijph_2021_1604371 crossref_primary_10_3390_nu13093135 crossref_primary_10_1016_j_jff_2025_106956 crossref_primary_10_1038_s41598_020_75227_x crossref_primary_10_3748_wjg_v29_i2_286 crossref_primary_10_3389_fnut_2021_716783 crossref_primary_10_1155_2019_8325102 crossref_primary_10_3390_jcm8081098 crossref_primary_10_3390_antiox9090857 crossref_primary_10_3390_nu12113395 crossref_primary_10_1016_j_molmet_2020_101049 crossref_primary_10_2196_37487 crossref_primary_10_1079_fsncases_2025_0014 crossref_primary_10_3390_ijms21218351 crossref_primary_10_1016_j_ajcnut_2023_11_013 crossref_primary_10_1089_met_2018_0072 crossref_primary_10_3389_fphar_2022_925264 crossref_primary_10_1016_j_clnesp_2023_06_027 crossref_primary_10_1007_s00535_024_02157_0 crossref_primary_10_1016_S2468_1253_22_00008_5 crossref_primary_10_4103_ijpvm_ijpvm_284_22 crossref_primary_10_3390_ijms26020782 crossref_primary_10_1038_s41598_023_43509_9 crossref_primary_10_1002_advs_201801585 crossref_primary_10_1016_j_jff_2023_105714 crossref_primary_10_3390_microorganisms9050957 crossref_primary_10_2147_DMSO_S439127 |
| Cites_doi | 10.1038/ejcn.2014.8 10.1002/hep.26717 10.2337/dc14-S014 10.1016/j.jhep.2015.02.041 10.1056/NEJMoa1401329 10.1002/hep.24127 10.1016/j.jhep.2004.09.012 10.1053/j.gastro.2007.04.068 10.1002/hep.26156 10.3390/nu5051544 10.1002/hep.23789 10.1111/liv.12584 10.1016/j.cgh.2006.09.025 10.1016/j.jhep.2011.11.016 10.1053/j.gastro.2011.06.061 10.1038/ajg.2012.331 10.1016/j.jhep.2011.08.018 10.1007/BF00280883 10.1210/jc.2014-3050 10.2337/dc14-0937 10.1007/s00125-013-3149-9 10.1016/j.jhep.2014.11.034 10.1002/hep.20842 10.1111/liv.12304 10.1152/ajpendo.00133.2006 10.1002/hep.20701 10.1016/j.jhep.2015.05.006 10.1016/j.jhep.2012.02.023 10.1038/nrgastro.2013.41 10.1038/ijo.2011.100 10.1053/jlts.2002.36740 10.1016/j.jhep.2013.04.027 10.1016/j.jhep.2010.04.008 10.2337/dc11-1849 10.1111/apt.12038 10.1016/j.jhep.2014.08.036 10.1016/j.jhep.2013.08.011 10.1016/S2213-8587(14)70032-4 10.1002/hep.22575 10.1210/jc.2012-1267 10.1111/j.1365-2036.2005.02602.x 10.1016/j.cld.2013.09.009 10.1111/j.1365-2036.2011.04724.x 10.1053/j.gastro.2014.04.046 10.1002/hep.21984 10.1136/bmj.39489.470347.AD 10.1016/j.jhep.2009.10.010 10.1016/j.jhep.2013.07.042 10.2337/dc07-1463 10.2337/diabetes.51.10.3025 10.1053/j.gastro.2005.03.084 10.1002/hep.23276 10.1053/j.gastro.2015.04.005 10.1002/hep.23425 10.1002/hep.23312 10.1038/ncomms5309 10.1016/S0140-6736(12)60525-X 10.1016/j.jhep.2012.11.021 10.1002/hep.23622 10.1136/bmj.d7771 10.1053/j.gastro.2008.03.078 10.1053/j.gastro.2009.03.019 10.1002/hep.27368 10.1002/hep.23727 10.1056/NEJMoa0907929 10.2337/diabetes.53.8.2169 10.1002/hep.20734 10.1016/j.jhep.2015.04.006 10.1530/EJE-13-0296 10.1016/j.cmet.2015.04.004 10.1097/SLA.0000000000000945 10.1093/eurheartj/ehr453 10.2337/diabetes.54.3.603 10.1016/j.jhep.2011.06.010 10.1002/hep.22724 10.3748/wjg.15.6017 10.1002/hep.23527 10.1007/s00125-010-1720-1 10.1136/bmj.c5702 10.1136/gut.2008.171280 10.1016/j.cgh.2013.09.023 10.1002/hep.25772 10.1111/liv.12230 10.1111/j.1572-0241.2007.01192.x 10.1111/apt.12963 10.1016/S0140-6736(14)61933-4 10.1002/hep.24544 10.7326/0003-4819-132-2-200001180-00004 10.2337/dc10-0856 10.1097/00004836-200508000-00012 10.1097/MEG.0b013e32835d72cf 10.1097/MD.0b013e3182779d49 10.1371/journal.pmed.1001680 10.1111/apt.12543 10.1002/hep.23270 10.1002/hep.20092 10.1097/MPG.0000000000000279 10.1136/heartjnl-2013-305099 10.1038/ijo.2011.247 10.1097/MPG.0b013e318252a13f 10.1016/j.jhep.2012.03.024 10.1002/hep.27647 10.1002/hep.23823 10.1016/j.jhep.2004.02.013 10.1016/j.jhep.2011.04.022 10.1053/j.gastro.2013.05.042 10.1016/S0140-6736(15)00803-X 10.1002/hep.25762 10.1177/1756283X09105462 10.1002/hep.22429 10.1016/j.jhep.2012.12.003 10.1002/hep.26986 10.1016/j.jhep.2014.10.023 10.1111/apt.12972 10.1038/nrgastro.2012.200 10.1016/j.cld.2013.09.005 10.1016/j.jhep.2013.02.012 10.1002/hep.26393 10.1016/j.atherosclerosis.2013.07.052 10.1158/1940-6207.CAPR-11-0228 10.1111/apt.12569 10.1186/1471-230X-14-166 10.1016/j.cgh.2006.02.004 10.1016/j.jhep.2014.02.030 10.1080/00365520902845268 10.1001/jama.2011.520 10.1001/jama.297.8.842 10.1002/hep.27173 10.3748/wjg.v20.i11.3002 10.1016/j.cgh.2014.04.014 10.1001/jama.2011.1437 10.3748/wjg.v17.i29.3377 10.1038/ajg.2012.20 10.1053/j.gastro.2008.06.047 10.1055/s-0032-1306421 10.1016/j.cgh.2014.05.010 10.1016/j.jhep.2012.07.027 10.1002/hep.27490 10.1053/gast.2002.35354 10.1056/NEJMra0912063 10.1111/apt.12352 10.1111/j.1572-0241.2005.41583.x 10.1056/NEJMoa060326 10.1002/hep.24356 10.1053/j.gastro.2015.04.014 10.1159/000339344 10.1002/hep.27678 |
| ContentType | Journal Article |
| Copyright | 2016 S. Karger AG, Basel Copyright © 2016 by S. Karger GmbH, Freiburg 2016 |
| Copyright_xml | – notice: 2016 S. Karger AG, Basel – notice: Copyright © 2016 by S. Karger GmbH, Freiburg 2016 |
| CorporateAuthor | European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) |
| CorporateAuthor_xml | – name: European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) – name: European Association for the Study of Diabetes (EASD) – name: European Association for the Study of Obesity (EASO) – name: European Association for the Study of the Liver (EASL) |
| DBID | M-- AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1159/000443344 |
| DatabaseName | Karger Open Access Journals CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ : Directory of Open Access Journals [open access] |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher – sequence: 4 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1662-4033 |
| EndPage | 90 |
| ExternalDocumentID | oai_doaj_org_article_a7b4b6183da1413ebbc1d43bd9aa5eba PMC5644799 27055256 10_1159_000443344 443344 |
| Genre | Journal Article |
| GroupedDBID | --- 0R~ 0~B 123 3O. 4.4 53G 5VS AAKDD AAYIC ABPAZ ACGFS ADBBV AENEX AEYAO AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV CS3 CYUIP DU5 E0A EBS EJD EMOBN F5P FB. GROUPED_DOAJ HYE HZ~ IAO IHR IHW IPNFZ KQ8 KUZGX M-- N9A O1H O9- OK1 RIG RKO RNS RPM UJ6 7WY 7X7 883 88E 8FI 8FJ 8FL 8G5 AAYXX ABBTS ABUWG ABWCG AFFHD AFJJK AFKRA AHFRZ AZPMC AZQEC BENPR BEZIV BPHCQ BVXVI CAG CCPQU CITATION COF DWQXO FRNLG FYUFA GNUQQ GUQSH HMCUK ITC K60 K6~ M0F M1P M2O OVD PADUT PHGZM PHGZT PJZUB PPXIY PQBIZ PQBZA PQQKQ PROAC PSQYO TEORI UKHRP 3V. NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c4714-c2fc0e6b3482ee85b6f7fb32e5d376911694202ade9b63f4bc73481218b28c7f3 |
| IEDL.DBID | DOA |
| ISSN | 1662-4025 |
| IngestDate | Fri Oct 03 12:44:45 EDT 2025 Thu Aug 21 18:21:43 EDT 2025 Thu Sep 04 17:19:10 EDT 2025 Wed Feb 19 02:41:26 EST 2025 Sat Nov 29 08:01:38 EST 2025 Tue Nov 18 21:57:12 EST 2025 Thu Aug 29 12:04:43 EDT 2024 Thu Sep 05 19:48:33 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. https://creativecommons.org/licenses/by-nc-nd/4.0 This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4714-c2fc0e6b3482ee85b6f7fb32e5d376911694202ade9b63f4bc73481218b28c7f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These guidelines were developed by the EASL, EASD and the EASO, and are being published simultaneously in the Journal of Hepatology, Diabetologia and Obesity Facts. Contributors: Coordinator EASL: Giulio Marchesini; Panel Members: Christopher P. Day, Jean-François Dufour, Ali Canbay, Valerio Nobili, Vlad Ratziu, Herbert Tilg; Coordinator EASD: Michael Roden; Panel Members: Amalia Gastaldelli, Hannele Yki-Järvinen, Fritz Schick; Coordinator EASO: Roberto Vettor, Panel Members: Gema Frühbeck, Lisbeth Mathus-Vliegen. |
| OpenAccessLink | https://doaj.org/article/a7b4b6183da1413ebbc1d43bd9aa5eba |
| PMID | 27055256 |
| PQID | 1783920419 |
| PQPubID | 23479 |
| PageCount | 26 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a7b4b6183da1413ebbc1d43bd9aa5eba proquest_miscellaneous_1783920419 karger_primary_443344 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5644799 pubmed_primary_27055256 crossref_citationtrail_10_1159_000443344 crossref_primary_10_1159_000443344 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-00-00 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – year: 2016 text: 2016-00-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Wilhelmstrasse 20A, P.O. Box · Postfach · Case postale, D–79095, Freiburg, Germany · Deutschland · Allemagne, Phone: +49 761 45 20 70, Fax: +49 761 4 52 07 14, information@karger.de |
| PublicationTitle | Obesity facts |
| PublicationTitleAlternate | Obes Facts |
| PublicationYear | 2016 |
| Publisher | S. Karger GmbH Karger Publishers |
| Publisher_xml | – name: S. Karger GmbH – name: Karger Publishers |
| References | Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, et al: Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:e2121-e2122.24846279 10.1016/j.cgh.2014.05.010 Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho GY, et al: Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014;100:938-943.24721975 10.1136/heartjnl-2013-305099 Llaurado G, Sevastianova K, Sadevirta S, Hakkarainen A, Lundbom N, Orho-Melander M, et al: Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. J Clin Endocrinol Metab 2015;100:607-616.25405502 10.1210/jc.2014-3050 Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-1544.19625277 10.1136/gut.2008.171280 Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al: Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251-1258.17391316 10.1111/j.1572-0241.2007.01192.x Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.15895401 10.1002/hep.20734 Kleiner DE, Brunt EM: Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012;32:3-13.22418883 10.1055/s-0032-1306421 Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al: Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-951.22505194 10.1002/hep.25772 Marchesini G, Mazzotti A: NAFLD incidence and remission: only a matter of weight gain and weight loss? J Hepatol 2015;62:15-17.25450705 10.1016/j.jhep.2014.10.023 Keating SE, Hackett DA, George J, Johnson NA: Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;57:157-166.22414768 10.1016/j.jhep.2012.02.023 Saab S, Mallam D, Cox 2nd GA, Tong MJ: Impact of coffee on liver diseases: a systematic review. Liver Int 2014;34:495-504.24102757 10.1111/liv.12304 Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:e571.2372726410.1053/j.gastro.2013.05.042 Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, et al: Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015;61:1239-1250.25482832 10.1002/hep.27647 Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010;341:c5702.21051774 10.1136/bmj.c5702 Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al: Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-649.16116629 10.1002/hep.20842 Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, et al: Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther 2012;36:772-781.22958053 10.1111/apt.12038 Heuer M, Kaiser GM, Kahraman A, Banysch M, Saner FH, Mathe Z, et al: Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 2012;86:107-113.22846254 10.1159/000339344 Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, et al: Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 2014;68:416-423.24569542 10.1038/ejcn.2014.8 Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al: Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:809-820.19142989 10.1002/hep.22724 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.3899825 10.1007/BF00280883 Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al: Adaptation of hepatic mitochondrial function in humans with nonalcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015;21:739-746.25955209 10.1016/j.cmet.2015.04.004 Ratziu V, Goodman Z, Sanyal A: Current efforts and trends in the treatment of NASH. J Hepatol 2015;62:S65-S75.25920092 10.1016/j.jhep.2015.02.041 Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L: Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14.24206433 10.1111/apt.12543 Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, et al: Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862-1871.23032979 10.1038/ajg.2012.331 Ryan CK, Johnson LA, Germin BI, Marcos A: One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002;8:1114-1122.12474149 10.1053/jlts.2002.36740 Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al: Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610-1619.21748765 10.1002/hep.24544 Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, et al: The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014;57:878-890.24407920 10.1007/s00125-013-3149-9 Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE: Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and metaanalysis. J Clin Endocrinol Metab 2012;97:2347-2353.22523334 10.1210/jc.2012-1267 Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54:603-608.15734833 10.2337/diabetes.54.3.603 Wong RJ, Cheung R, Ahmed A: Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.. Hepatology 2014;59:2188-2195.24375711 10.1002/hep.26986 Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al: Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012;35:873-878.22374640 10.2337/dc11-1849 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM: Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148-1155.25477264 10.1016/j.jhep.2014.11.034 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-1668.21521847 10.1001/jama.2011.520 Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-1978.20209604 10.1002/hep.23527 Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:e391.24076414 10.1016/j.cgh.2013.09.023 Rodriguez B, Torres DM, Harrison SA: Physical activity: an essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol 2012;9:726-731.23090329 10.1038/nrgastro.2012.200 Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, et al: TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309.24978903 10.1038/ncomms5309 Yki-Järvinen H: Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901-910.24731669 10.1016/S2213-8587(14)70032-4 Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, et al: Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44:853-860.19811343 10.1080/00365520902845268 Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G: The role of medications for the management of patients with NAFLD. Clin Liver Dis 2014;18:73-89.24274866 10.1016/j.cld.2013.09.005 Mitchel EB, Lavine JE: Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1155-1170.25267322 10.1111/apt.12972 Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al: Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008;31:165-169.17934148 10.2337/dc07-1463 Dyson J, Jaques B, Chattopady ref57 ref56 ref59 ref58 ref53 ref52 ref55 ref54 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref100 ref101 ref40 ref35 ref34 ref37 ref36 ref31 ref30 ref33 ref146 ref32 ref147 ref39 ref38 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref13 ref12 ref15 ref128 ref14 ref129 ref97 ref126 ref96 ref127 ref11 ref99 ref124 ref10 ref98 ref125 ref17 ref16 ref19 ref18 ref93 ref133 ref92 ref134 ref95 ref131 ref94 ref132 ref130 ref91 ref90 ref89 ref139 ref86 ref137 ref85 ref138 ref88 ref135 ref87 ref136 ref82 ref144 ref81 ref145 ref84 ref142 ref83 ref143 ref140 ref141 ref80 ref79 ref108 ref78 ref109 ref106 ref107 ref75 ref104 ref74 ref105 ref77 ref102 ref76 ref103 ref2 ref1 ref71 ref111 ref70 ref112 ref73 ref72 ref110 ref68 ref119 ref67 ref117 ref69 ref118 ref64 ref115 ref63 ref116 ref66 ref113 ref65 ref114 ref60 ref122 ref123 ref62 ref120 ref61 ref121 25379859 - Ann Surg. 2014 Nov;260(5):893-8; discussion 898-9 25911335 - J Hepatol. 2015 Jul;63(1):237-64 22158268 - Int J Obes (Lond). 2012 Sep;36(9):1187-94 12198701 - Gastroenterology. 2002 Sep;123(3):745-50 19318102 - Gastroenterology. 2009 May;136(5):1490-2 23175136 - Hepatology. 2013 Apr;57(4):1357-65 23117851 - Medicine (Baltimore). 2012 Nov;91(6):319-27 18752331 - Hepatology. 2008 Sep;48(3):792-8 25260964 - BMC Gastroenterol. 2014 Sep 27;14:166 22236411 - BMJ. 2012 Jan 10;344:d7771 21587201 - Int J Obes (Lond). 2012 Feb;36(2):286-94 23809459 - Liver Int. 2014 Jan;34(1):129-35 18436948 - BMJ. 2008 Apr 26;336(7650):924-6 17934148 - Diabetes Care. 2008 Jan;31(1):165-9 25482832 - Hepatology. 2015 Apr;61(4):1239-50 18038452 - Hepatology. 2008 Feb;47(2):455-60 22414768 - J Hepatol. 2012 Jul;57(1):157-66 24308774 - Aliment Pharmacol Ther. 2014 Feb;39(3):254-69 24768810 - Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40 20648474 - Hepatology. 2010 Oct;52(4):1274-80 23090329 - Nat Rev Gastroenterol Hepatol. 2012 Dec;9(12):726-31 25980762 - J Hepatol. 2015 Sep;63(3):705-12 21319198 - Hepatology. 2011 Mar;53(3):810-20 25917783 - Gastroenterology. 2015 Aug;149(2):379-88; quiz e15-6 19827166 - Hepatology. 2010 Jan;51(1):121-9 20664019 - Diabetes Care. 2010 Oct;33(10):2156-63 25477264 - J Hepatol. 2015 May;62(5):1148-55 23507799 - Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44 22958053 - Aliment Pharmacol Ther. 2012 Oct;36(8):772-81 19625277 - Gut. 2009 Nov;58(11):1538-44 17162245 - Clin Gastroenterol Hepatol. 2006 Dec;4(12):1537-43 23032979 - Am J Gastroenterol. 2012 Dec;107(12):1862-71 23238106 - J Hepatol. 2013 Jun;58(6):1218-29 18718471 - Gastroenterology. 2008 Oct;135(4):1176-84 25011950 - Diabetes Care. 2014 Oct;37(10):2813-21 20027672 - World J Gastroenterol. 2009 Dec 28;15(48):6017-22 20658466 - Hepatology. 2010 Sep;52(3):1156-61 22683134 - Lancet. 2012 Jun 16;379(9833):2243-51 22488764 - Hepatology. 2012 Jun;55(6):2005-23 22173152 - J Hepatol. 2012 Apr;56(4):840-7 22846254 - Digestion. 2012;86(2):107-13 15842582 - Am J Gastroenterol. 2005 May;100(5):1082-90 15895401 - Hepatology. 2005 Jul;42(1):44-52 19877169 - Hepatology. 2010 Feb;51(2):445-53 23973932 - J Hepatol. 2014 Jan;60(1):167-74 23653455 - Eur J Endocrinol. 2013 Jun 29;169(2):R27-37 20063276 - Hepatology. 2010 Mar;51(3):828-35 25920092 - J Hepatol. 2015 Apr;62(1 Suppl):S65-75 20494470 - J Hepatol. 2010 Aug;53(2):372-84 19053049 - Hepatology. 2009 Jan;49(1):80-6 24206433 - Aliment Pharmacol Ther. 2014 Jan;39(1):3-14 15030972 - J Hepatol. 2004 Apr;40(4):578-84 24846279 - Clin Gastroenterol Hepatol. 2014 Dec;12(12):2121-30.e1-2 24274867 - Clin Liver Dis. 2014 Feb;18(1):91-112 15940625 - Gastroenterology. 2005 Jun;128(7):1898-906 25267215 - Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22 19811343 - Scand J Gastroenterol. 2009;44(7):853-60 24274866 - Clin Liver Dis. 2014 Feb;18(1):73-89 24978903 - Nat Commun. 2014 Jun 30;5:4309 25083079 - World J Gastroenterol. 2014 Jul 21;20(27):9055-71 20683947 - Hepatology. 2010 Aug;52(2):472-9 25955209 - Cell Metab. 2015 May 5;21(5):739-46 22395188 - J Pediatr Gastroenterol Nutr. 2012 May;54(5):700-13 14999696 - Hepatology. 2004 Mar;39(3):770-8 23718573 - Aliment Pharmacol Ther. 2013 Jul;38(2):134-43 20209604 - Hepatology. 2010 Jun;51(6):1972-8 25865049 - Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5 23978719 - J Hepatol. 2014 Jan;60(1):110-7 23485520 - J Hepatol. 2013 Jul;59(1):138-43 23183525 - J Hepatol. 2013 May;58(5):1007-19 22871498 - J Hepatol. 2012 Dec;57(6):1312-8 19142989 - Hepatology. 2009 Mar;49(3):809-20 24731669 - Lancet Diabetes Endocrinol. 2014 Nov;2(11):901-10 24818764 - Gastroenterology. 2014 Aug;147(2):377-84.e1 24659891 - World J Gastroenterol. 2014 Mar 21;20(11):3002-10 12351443 - Diabetes. 2002 Oct;51(10):3025-32 20101745 - Hepatology. 2010 Feb;51(2):454-62 18503774 - Gastroenterology. 2008 Jul;135(1):100-10 24357209 - Diabetes Care. 2014 Jan;37 Suppl 1:S14-80 24679060 - N Engl J Med. 2014 May 22;370(21):2002-13 19897272 - J Hepatol. 2010 Jan;52(1):112-6 21703181 - J Hepatol. 2012 Jan;56(1):225-33 17327526 - JAMA. 2007 Feb 28;297(8):842-57 21521847 - JAMA. 2011 Apr 27;305(16):1659-68 24345846 - J Pediatr Gastroenterol Nutr. 2014 May;58(5):632-6 20369224 - Diabetologia. 2010 Jul;53(7):1341-8 21726509 - Gastroenterology. 2011 Oct;141(4):1249-53 23325287 - Eur J Gastroenterol Hepatol. 2013 Jun;25(6):652-8 15915461 - Hepatology. 2005 Jun;41(6):1313-21 26608256 - Lancet. 2016 Feb 13;387(10019):679-90 23504926 - Hepatology. 2013 Oct;58(4):1287-95 22374640 - Diabetes Care. 2012 Apr;35(4):873-8 24102757 - Liver Int. 2014 Apr;34(4):495-504 22418883 - Semin Liver Dis. 2012 Feb;32(1):3-13 17135584 - N Engl J Med. 2006 Nov 30;355(22):2297-307 22408036 - Eur Heart J. 2012 May;33(10):1190-200 25195547 - J Hepatol. 2015 Jan;62(1):190-7 21180541 - Therap Adv Gastroenterol. 2009 May;2(3):157-63 3899825 - Diabetologia. 1985 Jul;28(7):412-9 24753132 - Hepatology. 2014 Aug;60(2):565-75 24569542 - Eur J Clin Nutr. 2014 Apr;68(4):416-23 15629518 - J Hepatol. 2005 Jan;42(1):132-8 22023985 - J Hepatol. 2012 Apr;56(4):944-51 22523334 - J Clin Endocrinol Metab. 2012 Jul;97(7):2347-53 17090752 - Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E829-35 24407920 - Diabetologia. 2014 May;57(5):878-90 21051774 - BMJ. 2010 Nov 04;341:c5702 15734833 - Diabetes. 2005 Mar;54(3):603-8 17391316 - Am J Gastroenterol. 2007 Jun;102(6):1251-8 25468160 - Lancet. 2015 Mar 14;385(9972):956-65 23727264 - Gastroenterology. 2013 Sep;145(3):574-82.e1 21723839 - J Hepatol. 2012 Jan;56(1):255-66 21748765 - Hepatology. 2011 Nov;54(5):1610-9 20427778 - N Engl J Med. 2010 May 6;362(18):1675-85 22521357 - J Hepatol. 2012 Aug;57(2):384-91 24002776 - Hepatology. 2014 Mar;59(3):1174-97 17681171 - Gastroenterology. 2007 Aug;133(2):496-506 16116629 - Hepatology. 2005 Sep;42(3):641-9 25251399 - Hepatology. 2015 Feb;61(2):506-14 22505194 - Hepatology. 2012 Sep;56(3):943-51 24075754 - Atherosclerosis. 2013 Oct;230(2):258-67 21623852 - Aliment Pharmacol Ther. 2011 Aug;34(3):274-85 24375711 - Hepatology. 2014 Jun;59(6):2188-95 24076414 - Clin Gastroenterol Hepatol. 2014 Mar;12(3):394-402.e1 10644271 - Ann Intern Med. 2000 Jan 18;132(2):112-7 21990298 - JAMA. 2011 Oct 12;306(14):1549-56 22764020 - Am J Gastroenterol. 2012 Jul;107(7):976-8 23666091 - Nutrients. 2013 May 10;5(5):1544-60 24607626 - J Hepatol. 2014 Jul;61(1):75-81 24721975 - Heart. 2014 Jun;100(12):938-43 25557690 - Hepatology. 2015 Apr;61(4):1392-405 16225479 - Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:74-8 24798049 - Liver Int. 2015 May;35(5):1566-73 25125077 - Hepatology. 2015 May;61(5):1547-54 22467080 - Cancer Prev Res (Phila). 2012 Apr;5(4):544-52 25450705 - J Hepatol. 2015 Jan;62(1):15-7 25405502 - J Clin Endocrinol Metab. 2015 Feb;100(2):607-16 16000931 - J Clin Gastroenterol. 2005 Aug;39(7):619-25 15277403 - Diabetes. 2004 Aug;53(8):2169-76 23665288 - J Hepatol. 2013 Sep;59(3):550-6 25267322 - Aliment Pharmacol Ther. 2014 Nov;40(10):1155-70 21876630 - World J Gastroenterol. 2011 Aug 7;17(29):3377-89 20879883 - N Engl J Med. 2010 Sep 30;363(14 ):1341-50 16630771 - Clin Gastroenterol Hepatol. 2006 May;4(5):639-44 12474149 - Liver Transpl. 2002 Dec;8(12):1114-22 21488080 - Hepatology. 2011 Jul;54(1):145-52 20373368 - Hepatology. 2010 Apr;51(4):1209-17 25050550 - PLoS Med. 2014 Jul 22;11(7):e1001680 |
| References_xml | – reference: Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-778.1499969610.1002/hep.20092 – reference: Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al: Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:809-820.19142989 10.1002/hep.22724 – reference: McPherson S, Anstee QM, Henderson E, Day CP, Burt AD: Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol 2013;25:652-658.23325287 10.1097/MEG.0b013e32835d72cf – reference: Ghouri N, Preiss D, Sattar N: Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010;52:1156-1161.20658466 10.1002/hep.23789 – reference: Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, et al: The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014;57:878-890.24407920 10.1007/s00125-013-3149-9 – reference: Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE: Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-2251.22683134 10.1016/S0140-6736(12)60525-X – reference: Alkhouri N, De Vito R, Alisi A, Yerian L, Lopez R, Feldstein AE, et al: Development and validation of a new histological score for pediatric nonalcoholic fatty liver disease. J Hepatol 2012;57:1312-1318.22871498 10.1016/j.jhep.2012.07.027 – reference: Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al: Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012;91:319-327.23117851 10.1097/MD.0b013e3182779d49 – reference: Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.18436948 10.1136/bmj.39489.470347.AD – reference: Bedossa PFLIP Pathology Consortium: Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014;60:565-575.24753132 10.1002/hep.27173 – reference: Kim D, Kim WR, Kim HJ, Therneau TM: Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-1365.23175136 10.1002/hep.26156 – reference: Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho GY, et al: Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014;100:938-943.24721975 10.1136/heartjnl-2013-305099 – reference: Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA: Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009;49:80-86.19053049 10.1002/hep.22575 – reference: Boden G: High- or low-carbohydrate diets: which is better for weight loss, insulin resistance, and fatty livers? Gastroenterology 2009;136:1490-1492.1931810210.1053/j.gastro.2009.03.019 – reference: Alberti A, Vario A, Ferrari A, Pistis R: Review article: chronic hepatitis C- natural history and cofactors. Aliment Pharmacol Ther 2005;22:74-78.16225479 10.1111/j.1365-2036.2005.02602.x – reference: Caldwell SH, Crespo DM: The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004;40:578-584.15030972 10.1016/j.jhep.2004.02.013 – reference: Kleiner DE, Brunt EM: Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012;32:3-13.22418883 10.1055/s-0032-1306421 – reference: Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184.18718471 10.1053/j.gastro.2008.06.047 – reference: Nobili V, Donati B, Panera N, Vongsakulyanon A, Alisi A, Dallapiccola B, et al: A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2014;58:632-636.24345846 10.1097/MPG.0000000000000279 – reference: Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-285.2162385210.1111/j.1365-2036.2011.04724.x – reference: Adams LA, Sanderson S, Lindor KD, Angulo P: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138.1562951810.1016/j.jhep.2004.09.012 – reference: Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al: Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610-1619.21748765 10.1002/hep.24544 – reference: Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al: Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-453.19877169 10.1002/hep.23270 – reference: Kwon HK, Greenson JK, Conjeevaram HS: Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int 2014;34:129-135.23809459 10.1111/liv.12230 – reference: Machado MV, Cortez-Pinto H: Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58:1007-1019.23183525 10.1016/j.jhep.2012.11.021 – reference: Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al: Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1209-1222.25267215 10.1111/apt.12963 – reference: Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al: Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-951.22505194 10.1002/hep.25772 – reference: Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL: Effects of glucagonlike peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771.22236411 10.1136/bmj.d7771 – reference: Liangpunsakul S, Chalasani N: What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol 2012;107:976-978.22764020 10.1038/ajg.2012.20 – reference: Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-129.19827166 10.1002/hep.23276 – reference: Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ: The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009;2:157-163.21180541 10.1177/1756283X09105462 – reference: Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, et al: I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010;52:1274-1280.20648474 10.1002/hep.23823 – reference: Heuer M, Kaiser GM, Kahraman A, Banysch M, Saner FH, Mathe Z, et al: Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 2012;86:107-113.22846254 10.1159/000339344 – reference: Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR: Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-820.21319198 10.1002/hep.24127 – reference: Hazlehurst JM, Tomlinson JW: Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 2013;169:R27-R37.23653455 10.1530/EJE-13-0296 – reference: Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al: Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554.25125077 10.1002/hep.27368 – reference: Klein EA, Thompson Jr IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al: Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-1556.2199029810.1001/jama.2011.1437 – reference: Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A, Bischof MG, et al: Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 2002;51:3025-3032.12351443 10.2337/diabetes.51.10.3025 – reference: Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al: A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013;59:550-556.23665288 10.1016/j.jhep.2013.04.027 – reference: Frith J, Day CP, Robinson L, Elliott C, Jones DE, Newton JL: Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 2010;52:112-116.19897272 10.1016/j.jhep.2009.10.010 – reference: Dongiovanni P, Petta S, Mannisto V, Margherita Mancina R, Pipitone R, Karja V, et al: Statin use and nonalcoholic steatohepatitis in at risk individuals. J Hepatol 2015;doi: 10.1016/j.jhep.2015.05.006.2598076210.1016/j.jhep.2015.05.006 – reference: Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.15915461 10.1002/hep.20701 – reference: Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al: Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680.25050550 10.1371/journal.pmed.1001680 – reference: Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al: Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100-110.18503774 10.1053/j.gastro.2008.03.078 – reference: Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA: Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-1253.21726509 10.1053/j.gastro.2011.06.061 – reference: Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, et al: Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862-1871.23032979 10.1038/ajg.2012.331 – reference: Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297:842-857.17327526 10.1001/jama.297.8.842 – reference: Chang Y, Ryu S, Suh BS, Yun KE, Kim CW, Cho SI: Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes (Lond) 2012;36:1187-1194.22158268 10.1038/ijo.2011.247 – reference: Barrera F, George J: The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis 2014;18:91-112.24274867 10.1016/j.cld.2013.09.009 – reference: Haflidadottir S, Jonasson JG, Norland H, Einarsdottir SO, Kleiner DE, Lund SH, et al: Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014;14:166.25260964 10.1186/1471-230X-14-166 – reference: Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906.15940625 10.1053/j.gastro.2005.03.084 – reference: Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.1713558410.1056/NEJMoa060326 – reference: Targher G, Day CP, Bonora E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-1350.20879883 10.1056/NEJMra0912063 – reference: Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54:603-608.15734833 10.2337/diabetes.54.3.603 – reference: Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al: Risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792-798.18752331 10.1002/hep.22429 – reference: Ratziu V, Goodman Z, Sanyal A: Current efforts and trends in the treatment of NASH. J Hepatol 2015;62:S65-S75.25920092 10.1016/j.jhep.2015.02.041 – reference: Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-1978.20209604 10.1002/hep.23527 – reference: Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, et al: Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther 2012;36:772-781.22958053 10.1111/apt.12038 – reference: Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.3899825 10.1007/BF00280883 – reference: Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE: Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and metaanalysis. J Clin Endocrinol Metab 2012;97:2347-2353.22523334 10.1210/jc.2012-1267 – reference: Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-1090.1584258210.1111/j.1572-0241.2005.41583.x – reference: Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, et al: A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014;20:3002-3010.24659891 10.3748/wjg.v20.i11.3002 – reference: Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, et al: TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309.24978903 10.1038/ncomms5309 – reference: Ryan CK, Johnson LA, Germin BI, Marcos A: One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002;8:1114-1122.12474149 10.1053/jlts.2002.36740 – reference: Gomez-Ambrosi J, Catalan V, Rodriguez A, Andrada P, Ramirez B, Ibanez P, et al: Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care 2014;37:2813-2821.25011950 10.2337/dc14-0937 – reference: Wong RJ, Cheung R, Ahmed A: Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.. Hepatology 2014;59:2188-2195.24375711 10.1002/hep.26986 – reference: Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V, et al: Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 2014;260:893-898, Discussion 898-899.25379859 10.1097/SLA.0000000000000945 – reference: Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-654, e641-e649; quiz e639-e640.24768810 10.1016/j.cgh.2014.04.014 – reference: Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, et al: Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133:496-506.1768117110.1053/j.gastro.2007.04.068 – reference: Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al: The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013;59:138-143.23485520 10.1016/j.jhep.2013.02.012 – reference: Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L: Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14.24206433 10.1111/apt.12543 – reference: McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM: Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148-1155.25477264 10.1016/j.jhep.2014.11.034 – reference: Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al: Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 2014;370:2002-2013.24679060 10.1056/NEJMoa1401329 – reference: Llaurado G, Sevastianova K, Sadevirta S, Hakkarainen A, Lundbom N, Orho-Melander M, et al: Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. J Clin Endocrinol Metab 2015;100:607-616.25405502 10.1210/jc.2014-3050 – reference: Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al: Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251-1258.17391316 10.1111/j.1572-0241.2007.01192.x – reference: Bhatia LS, Curzen NP, Calder PC, Byrne CD: Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33:1190-1200.22408036 10.1093/eurheartj/ehr453 – reference: Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:e391.24076414 10.1016/j.cgh.2013.09.023 – reference: Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al: Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-460.18038452 10.1002/hep.21984 – reference: Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.15895401 10.1002/hep.20734 – reference: Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, et al: Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015;61:1239-1250.25482832 10.1002/hep.27647 – reference: Marchesini G, Mazzotti A: NAFLD incidence and remission: only a matter of weight gain and weight loss? J Hepatol 2015;62:15-17.25450705 10.1016/j.jhep.2014.10.023 – reference: Thoma C, Day CP, Trenell MI: Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012;56:255-266.21723839 10.1016/j.jhep.2011.06.010 – reference: Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, et al: Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012;54:700-713.22395188 10.1097/MPG.0b013e318252a13f – reference: Zelber-Sagi S, Ratziu V, Oren R: Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 2011;17:3377-3389.21876630 10.3748/wjg.v17.i29.3377 – reference: Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.1064427110.7326/0003-4819-132-2-200001180-00004 – reference: Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, et al: Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013;38:134-143.23718573 10.1111/apt.12352 – reference: Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F, et al: Adaptation of hepatic mitochondrial function in humans with nonalcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015;21:739-746.25955209 10.1016/j.cmet.2015.04.004 – reference: Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, et al: Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.24607626 10.1016/j.jhep.2014.02.030 – reference: Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al: Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012;35:873-878.22374640 10.2337/dc11-1849 – reference: Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G: The role of medications for the management of patients with NAFLD. Clin Liver Dis 2014;18:73-89.24274866 10.1016/j.cld.2013.09.005 – reference: Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010;341:c5702.21051774 10.1136/bmj.c5702 – reference: Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases, United States Food and Drug Administration: Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology 2015;61:1392-1405.25557690 10.1002/hep.27678 – reference: Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al: The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.22488764 10.1002/hep.25762 – reference: Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al: Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014;60:167-174.23973932 10.1016/j.jhep.2013.07.042 – reference: Yki-Järvinen H: Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901-910.24731669 10.1016/S2213-8587(14)70032-4 – reference: Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, et al: High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:472-479.20683947 10.1002/hep.23727 – reference: Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J: Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944-951.22023985 10.1016/j.jhep.2011.08.018 – reference: Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Järvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.1527740310.2337/diabetes.53.8.2169 – reference: Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, et al: Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 2012;5:544-552.22467080 10.1158/1940-6207.CAPR-11-0228 – reference: Aron-Wisnewsky J, Minville C, Tordjman J, Levy P, Bouillot JL, Basdevant A, et al: Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012;56:225-233.21703181 10.1016/j.jhep.2011.04.022 – reference: Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, et al: Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 2014;68:416-423.24569542 10.1038/ejcn.2014.8 – reference: Castera L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al: Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010;51:828-835.20063276 10.1002/hep.23425 – reference: Petta S, Vanni E, Bugianesi E, Di Marco V, Camma C, Cabibi D, et al: The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015;35:1566-1573.24798049 10.1111/liv.12584 – reference: Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al: Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014;60:110-117.23978719 10.1016/j.jhep.2013.08.011 – reference: Nobili V, Alisi A, Raponi M: Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009;15:6017-6022.20027672 10.3748/wjg.15.6017 – reference: Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, et al: Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010;53:1341-1348.20369224 10.1007/s00125-010-1720-1 – reference: Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.20427778 10.1056/NEJMoa0907929 – reference: Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al: Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367-378.e5; quiz e14-e15.25865049 10.1053/j.gastro.2015.04.005 – reference: Rodriguez B, Torres DM, Harrison SA: Physical activity: an essential component of lifestyle modification in NAFLD. Nat Rev Gastroenterol Hepatol 2012;9:726-731.23090329 10.1038/nrgastro.2012.200 – reference: Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-1668.21521847 10.1001/jama.2011.520 – reference: Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al: Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-1217.20373368 10.1002/hep.23622 – reference: Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, et al: Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008;31:165-169.17934148 10.2337/dc07-1463 – reference: Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group: No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014;147:e377-384.e1.24818764 10.1053/j.gastro.2014.04.046 – reference: Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P: A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2013;58:1218-1229.23238106 10.1016/j.jhep.2012.12.003 – reference: Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750.12198701 10.1053/gast.2002.35354 – reference: Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al: A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013;230:258-267.24075754 10.1016/j.atherosclerosis.2013.07.052 – reference: Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, et al: Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013;58:1287-1295.23504926 10.1002/hep.26393 – reference: Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H: Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E829-E835.17090752 10.1152/ajpendo.00133.2006 – reference: American Diabetes Association: Standards of medical care in diabetes- 2014. Diabetes Care 2014;37:S14-S80.24357209 10.2337/dc14-S014 – reference: Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al: Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61:506-514.25251399 10.1002/hep.27490 – reference: Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A: Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;5:1544-1560.23666091 10.3390/nu5051544 – reference: Sebagh M, Samuel D, Antonini TM, Coilly A, Degli Esposti D, Roche B, et al: Twenty-year protocol liver biopsies: invasive but useful for the management of liver recipients. J Hepatol 2012;56:840-847.22173152 10.1016/j.jhep.2011.11.016 – reference: Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-462.20101745 10.1002/hep.23312 – reference: Gomez-Ambrosi J, Silva C, Galofre JC, Escalada J, Santos S, Millan D, et al: Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) 2012;36:286-294.21587201 10.1038/ijo.2011.100 – reference: Keating SE, Hackett DA, George J, Johnson NA: Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;57:157-166.22414768 10.1016/j.jhep.2012.02.023 – reference: Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384.20494470 10.1016/j.jhep.2010.04.008 – reference: Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al: Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-649.16116629 10.1002/hep.20842 – reference: Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, et al: Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005;39:619-625.16000931 10.1097/00004836-200508000-00012 – reference: Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al: Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-1543.17162245 10.1016/j.cgh.2006.09.025 – reference: Anstee QM, Targher G, Day CP: Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-344.23507799 10.1038/nrgastro.2013.41 – reference: Saab S, Mallam D, Cox 2nd GA, Tong MJ: Impact of coffee on liver diseases: a systematic review. Liver Int 2014;34:495-504.24102757 10.1111/liv.12304 – reference: European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado: EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-264.25911335 10.1016/j.jhep.2015.04.006 – reference: Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, et al: Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44:853-860.19811343 10.1080/00365520902845268 – reference: Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE, Weltman AL, et al: Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 2015;62:190-197.25195547 10.1016/j.jhep.2014.08.036 – reference: Mitchel EB, Lavine JE: Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1155-1170.25267322 10.1111/apt.12972 – reference: Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al: Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010;33:2156-2163.20664019 10.2337/dc10-0856 – reference: Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al: Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014;39:254-269.24308774 10.1111/apt.12569 – reference: Pacifico L, Chiesa C, Anania C, De Merulis A, Osborn JF, Romaggioli S, et al: Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol 2014;20:9055-9071.25083079 – reference: Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, et al: Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:e2121-e2122.24846279 10.1016/j.cgh.2014.05.010 – reference: Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al: Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015;149:377-388.25917783 10.1053/j.gastro.2015.04.014 – reference: Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al: Liraglutide safety and effi cacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2015;doi: 10.1016/S0140-6736(15)00803-X.2660825610.1016/S0140-6736(15)00803-X – reference: Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, et al: Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012;57:384-391.22521357 10.1016/j.jhep.2012.03.024 – reference: Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-1544.19625277 10.1136/gut.2008.171280 – reference: Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-965.25468160 10.1016/S0140-6736(14)61933-4 – reference: Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014;59:1174-1197.24002776 10.1002/hep.26717 – reference: Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, et al: Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011;54:145-152.21488080 10.1002/hep.24356 – reference: Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:e571.2372726410.1053/j.gastro.2013.05.042 – reference: Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al: A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-644.1663077110.1016/j.cgh.2006.02.004 – ident: ref10 doi: 10.1038/ejcn.2014.8 – ident: ref62 doi: 10.1002/hep.26717 – ident: ref63 doi: 10.2337/dc14-S014 – ident: ref125 doi: 10.1016/j.jhep.2015.02.041 – ident: ref141 doi: 10.1056/NEJMoa1401329 – ident: ref23 doi: 10.1002/hep.24127 – ident: ref121 doi: 10.1016/j.jhep.2004.09.012 – ident: ref59 doi: 10.1053/j.gastro.2007.04.068 – ident: ref70 doi: 10.1002/hep.26156 – ident: ref44 doi: 10.3390/nu5051544 – ident: ref58 doi: 10.1002/hep.23789 – ident: ref41 doi: 10.1111/liv.12584 – ident: ref86 doi: 10.1016/j.cgh.2006.09.025 – ident: ref147 doi: 10.1016/j.jhep.2011.11.016 – ident: ref144 doi: 10.1053/j.gastro.2011.06.061 – ident: ref40 doi: 10.1038/ajg.2012.331 – ident: ref135 doi: 10.1016/j.jhep.2011.08.018 – ident: ref48 doi: 10.1007/BF00280883 – ident: ref66 doi: 10.1210/jc.2014-3050 – ident: ref57 doi: 10.2337/dc14-0937 – ident: ref100 doi: 10.1007/s00125-013-3149-9 – ident: ref49 doi: 10.1016/j.jhep.2014.11.034 – ident: ref71 doi: 10.1002/hep.20842 – ident: ref115 doi: 10.1111/liv.12304 – ident: ref65 doi: 10.1152/ajpendo.00133.2006 – ident: ref21 doi: 10.1002/hep.20701 – ident: ref136 doi: 10.1016/j.jhep.2015.05.006 – ident: ref116 doi: 10.1016/j.jhep.2012.02.023 – ident: ref12 doi: 10.1038/nrgastro.2013.41 – ident: ref55 doi: 10.1038/ijo.2011.100 – ident: ref29 doi: 10.1053/jlts.2002.36740 – ident: ref50 doi: 10.1016/j.jhep.2013.04.027 – ident: ref1 doi: 10.1016/j.jhep.2010.04.008 – ident: ref64 doi: 10.2337/dc11-1849 – ident: ref11 doi: 10.1111/apt.12038 – ident: ref103 doi: 10.1016/j.jhep.2014.08.036 – ident: ref76 doi: 10.1016/j.jhep.2013.08.011 – ident: ref47 doi: 10.1016/S2213-8587(14)70032-4 – ident: ref90 doi: 10.1002/hep.22575 – ident: ref128 doi: 10.1210/jc.2012-1267 – ident: ref45 doi: 10.1111/j.1365-2036.2005.02602.x – ident: ref9 doi: 10.1016/j.cld.2013.09.009 – ident: ref4 doi: 10.1111/j.1365-2036.2011.04724.x – ident: ref101 doi: 10.1053/j.gastro.2014.04.046 – ident: ref36 doi: 10.1002/hep.21984 – ident: ref2 doi: 10.1136/bmj.39489.470347.AD – ident: ref52 doi: 10.1016/j.jhep.2009.10.010 – ident: ref33 doi: 10.1016/j.jhep.2013.07.042 – ident: ref60 doi: 10.2337/dc07-1463 – ident: ref67 doi: 10.2337/diabetes.51.10.3025 – ident: ref19 doi: 10.1053/j.gastro.2005.03.084 – ident: ref92 doi: 10.1002/hep.23276 – ident: ref119 doi: 10.1053/j.gastro.2015.04.005 – ident: ref39 doi: 10.1002/hep.23425 – ident: ref38 doi: 10.1002/hep.23312 – ident: ref15 doi: 10.1038/ncomms5309 – ident: ref108 doi: 10.1016/S0140-6736(12)60525-X – ident: ref31 doi: 10.1016/j.jhep.2012.11.021 – ident: ref13 doi: 10.1002/hep.23622 – ident: ref129 doi: 10.1136/bmj.d7771 – ident: ref87 doi: 10.1053/j.gastro.2008.03.078 – ident: ref106 doi: 10.1053/j.gastro.2009.03.019 – ident: ref24 doi: 10.1002/hep.27368 – ident: ref95 doi: 10.1002/hep.23727 – ident: ref94 doi: 10.1056/NEJMoa0907929 – ident: ref126 doi: 10.2337/diabetes.53.8.2169 – ident: ref51 doi: 10.1002/hep.20734 – ident: ref32 doi: 10.1016/j.jhep.2015.04.006 – ident: ref81 doi: 10.1530/EJE-13-0296 – ident: ref46 doi: 10.1016/j.cmet.2015.04.004 – ident: ref142 doi: 10.1097/SLA.0000000000000945 – ident: ref74 doi: 10.1093/eurheartj/ehr453 – ident: ref118 doi: 10.2337/diabetes.54.3.603 – ident: ref109 doi: 10.1016/j.jhep.2011.06.010 – ident: ref25 doi: 10.1002/hep.22724 – ident: ref138 doi: 10.3748/wjg.15.6017 – ident: ref114 doi: 10.1002/hep.23527 – ident: ref79 doi: 10.1007/s00125-010-1720-1 – ident: ref132 doi: 10.1136/bmj.c5702 – ident: ref140 doi: 10.1136/gut.2008.171280 – ident: ref145 doi: 10.1016/j.cgh.2013.09.023 – ident: ref61 doi: 10.1002/hep.25772 – ident: ref112 doi: 10.1111/liv.12230 – ident: ref137 doi: 10.1111/j.1572-0241.2007.01192.x – ident: ref30 doi: 10.1111/apt.12963 – ident: ref98 doi: 10.1016/S0140-6736(14)61933-4 – ident: ref96 doi: 10.1002/hep.24544 – ident: ref3 doi: 10.7326/0003-4819-132-2-200001180-00004 – ident: ref107 doi: 10.2337/dc10-0856 – ident: ref28 doi: 10.1097/00004836-200508000-00012 – ident: ref37 doi: 10.1097/MEG.0b013e32835d72cf – ident: ref5 doi: 10.1097/MD.0b013e3182779d49 – ident: ref78 doi: 10.1371/journal.pmed.1001680 – ident: ref123 doi: 10.1111/apt.12543 – ident: ref93 doi: 10.1002/hep.23270 – ident: ref82 doi: 10.1002/hep.20092 – ident: ref18 doi: 10.1097/MPG.0000000000000279 – ident: ref80 doi: 10.1136/heartjnl-2013-305099 – ident: ref56 doi: 10.1038/ijo.2011.247 – ident: ref42 doi: 10.1097/MPG.0b013e318252a13f – ident: ref113 doi: 10.1016/j.jhep.2012.03.024 – ident: ref102 doi: 10.1002/hep.27647 – ident: ref17 doi: 10.1002/hep.23823 – ident: ref53 doi: 10.1016/j.jhep.2004.02.013 – ident: ref54 doi: 10.1016/j.jhep.2011.04.022 – ident: ref134 doi: 10.1053/j.gastro.2013.05.042 – ident: ref104 doi: 10.1016/S0140-6736(15)00803-X – ident: ref8 doi: 10.1002/hep.25762 – ident: ref91 doi: 10.1177/1756283X09105462 – ident: ref6 doi: 10.1002/hep.22429 – ident: ref43 doi: 10.1016/j.jhep.2012.12.003 – ident: ref77 doi: 10.1002/hep.26986 – ident: ref7 doi: 10.1016/j.jhep.2014.10.023 – ident: ref139 doi: 10.1111/apt.12972 – ident: ref120 doi: 10.1038/nrgastro.2012.200 – ident: ref124 doi: 10.1016/j.cld.2013.09.005 – ident: ref110 doi: 10.1016/j.jhep.2013.02.012 – ident: ref117 doi: 10.1002/hep.26393 – ident: ref72 doi: 10.1016/j.atherosclerosis.2013.07.052 – ident: ref127 doi: 10.1158/1940-6207.CAPR-11-0228 – ident: ref34 doi: 10.1111/apt.12569 – ident: ref69 doi: 10.1186/1471-230X-14-166 – ident: ref85 doi: 10.1016/j.cgh.2006.02.004 – ident: ref14 doi: 10.1016/j.jhep.2014.02.030 – ident: ref89 doi: 10.1080/00365520902845268 – ident: ref97 doi: 10.1001/jama.2011.520 – ident: ref131 doi: 10.1001/jama.297.8.842 – ident: ref22 doi: 10.1002/hep.27173 – ident: ref99 doi: 10.3748/wjg.v20.i11.3002 – ident: ref68 doi: 10.1016/j.cgh.2014.04.014 – ident: ref133 doi: 10.1001/jama.2011.1437 – ident: ref105 doi: 10.3748/wjg.v17.i29.3377 – ident: ref111 doi: 10.1038/ajg.2012.20 – ident: ref88 doi: 10.1053/j.gastro.2008.06.047 – ident: ref20 doi: 10.1055/s-0032-1306421 – ident: ref35 doi: 10.1016/j.cgh.2014.05.010 – ident: ref26 doi: 10.1016/j.jhep.2012.07.027 – ident: ref16 doi: 10.1002/hep.27490 – ident: ref27 doi: 10.1053/gast.2002.35354 – ident: ref73 doi: 10.1056/NEJMra0912063 – ident: ref130 doi: 10.1111/apt.12352 – ident: ref83 doi: 10.1111/j.1572-0241.2005.41583.x – ident: ref84 doi: 10.1056/NEJMoa060326 – ident: ref75 doi: 10.1002/hep.24356 – ident: ref143 doi: 10.1053/j.gastro.2015.04.014 – ident: ref146 doi: 10.1159/000339344 – ident: ref122 doi: 10.1002/hep.27678 – reference: 19142989 - Hepatology. 2009 Mar;49(3):809-20 – reference: 20648474 - Hepatology. 2010 Oct;52(4):1274-80 – reference: 22395188 - J Pediatr Gastroenterol Nutr. 2012 May;54(5):700-13 – reference: 24002776 - Hepatology. 2014 Mar;59(3):1174-97 – reference: 24607626 - J Hepatol. 2014 Jul;61(1):75-81 – reference: 25251399 - Hepatology. 2015 Feb;61(2):506-14 – reference: 22488764 - Hepatology. 2012 Jun;55(6):2005-23 – reference: 26608256 - Lancet. 2016 Feb 13;387(10019):679-90 – reference: 25379859 - Ann Surg. 2014 Nov;260(5):893-8; discussion 898-9 – reference: 22683134 - Lancet. 2012 Jun 16;379(9833):2243-51 – reference: 23978719 - J Hepatol. 2014 Jan;60(1):110-7 – reference: 24659891 - World J Gastroenterol. 2014 Mar 21;20(11):3002-10 – reference: 20209604 - Hepatology. 2010 Jun;51(6):1972-8 – reference: 24978903 - Nat Commun. 2014 Jun 30;5:4309 – reference: 20658466 - Hepatology. 2010 Sep;52(3):1156-61 – reference: 24407920 - Diabetologia. 2014 May;57(5):878-90 – reference: 3899825 - Diabetologia. 1985 Jul;28(7):412-9 – reference: 21488080 - Hepatology. 2011 Jul;54(1):145-52 – reference: 24846279 - Clin Gastroenterol Hepatol. 2014 Dec;12(12):2121-30.e1-2 – reference: 25920092 - J Hepatol. 2015 Apr;62(1 Suppl):S65-75 – reference: 24768810 - Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40 – reference: 23117851 - Medicine (Baltimore). 2012 Nov;91(6):319-27 – reference: 25405502 - J Clin Endocrinol Metab. 2015 Feb;100(2):607-16 – reference: 24274866 - Clin Liver Dis. 2014 Feb;18(1):73-89 – reference: 21703181 - J Hepatol. 2012 Jan;56(1):225-33 – reference: 22523334 - J Clin Endocrinol Metab. 2012 Jul;97(7):2347-53 – reference: 15842582 - Am J Gastroenterol. 2005 May;100(5):1082-90 – reference: 25955209 - Cell Metab. 2015 May 5;21(5):739-46 – reference: 23653455 - Eur J Endocrinol. 2013 Jun 29;169(2):R27-37 – reference: 15734833 - Diabetes. 2005 Mar;54(3):603-8 – reference: 23809459 - Liver Int. 2014 Jan;34(1):129-35 – reference: 23727264 - Gastroenterology. 2013 Sep;145(3):574-82.e1 – reference: 25267215 - Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22 – reference: 19811343 - Scand J Gastroenterol. 2009;44(7):853-60 – reference: 12351443 - Diabetes. 2002 Oct;51(10):3025-32 – reference: 15915461 - Hepatology. 2005 Jun;41(6):1313-21 – reference: 21990298 - JAMA. 2011 Oct 12;306(14):1549-56 – reference: 15895401 - Hepatology. 2005 Jul;42(1):44-52 – reference: 17135584 - N Engl J Med. 2006 Nov 30;355(22):2297-307 – reference: 24753132 - Hepatology. 2014 Aug;60(2):565-75 – reference: 15030972 - J Hepatol. 2004 Apr;40(4):578-84 – reference: 22158268 - Int J Obes (Lond). 2012 Sep;36(9):1187-94 – reference: 18752331 - Hepatology. 2008 Sep;48(3):792-8 – reference: 21587201 - Int J Obes (Lond). 2012 Feb;36(2):286-94 – reference: 16116629 - Hepatology. 2005 Sep;42(3):641-9 – reference: 25195547 - J Hepatol. 2015 Jan;62(1):190-7 – reference: 23485520 - J Hepatol. 2013 Jul;59(1):138-43 – reference: 23665288 - J Hepatol. 2013 Sep;59(3):550-6 – reference: 25911335 - J Hepatol. 2015 Jul;63(1):237-64 – reference: 23507799 - Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44 – reference: 22958053 - Aliment Pharmacol Ther. 2012 Oct;36(8):772-81 – reference: 17681171 - Gastroenterology. 2007 Aug;133(2):496-506 – reference: 19827166 - Hepatology. 2010 Jan;51(1):121-9 – reference: 19897272 - J Hepatol. 2010 Jan;52(1):112-6 – reference: 25125077 - Hepatology. 2015 May;61(5):1547-54 – reference: 23090329 - Nat Rev Gastroenterol Hepatol. 2012 Dec;9(12):726-31 – reference: 25260964 - BMC Gastroenterol. 2014 Sep 27;14:166 – reference: 22408036 - Eur Heart J. 2012 May;33(10):1190-200 – reference: 21723839 - J Hepatol. 2012 Jan;56(1):255-66 – reference: 24102757 - Liver Int. 2014 Apr;34(4):495-504 – reference: 22236411 - BMJ. 2012 Jan 10;344:d7771 – reference: 16630771 - Clin Gastroenterol Hepatol. 2006 May;4(5):639-44 – reference: 24569542 - Eur J Clin Nutr. 2014 Apr;68(4):416-23 – reference: 24357209 - Diabetes Care. 2014 Jan;37 Suppl 1:S14-80 – reference: 20027672 - World J Gastroenterol. 2009 Dec 28;15(48):6017-22 – reference: 18503774 - Gastroenterology. 2008 Jul;135(1):100-10 – reference: 20879883 - N Engl J Med. 2010 Sep 30;363(14 ):1341-50 – reference: 15940625 - Gastroenterology. 2005 Jun;128(7):1898-906 – reference: 20664019 - Diabetes Care. 2010 Oct;33(10):2156-63 – reference: 24274867 - Clin Liver Dis. 2014 Feb;18(1):91-112 – reference: 16225479 - Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:74-8 – reference: 17162245 - Clin Gastroenterol Hepatol. 2006 Dec;4(12):1537-43 – reference: 23238106 - J Hepatol. 2013 Jun;58(6):1218-29 – reference: 24798049 - Liver Int. 2015 May;35(5):1566-73 – reference: 22846254 - Digestion. 2012;86(2):107-13 – reference: 23032979 - Am J Gastroenterol. 2012 Dec;107(12):1862-71 – reference: 21726509 - Gastroenterology. 2011 Oct;141(4):1249-53 – reference: 22374640 - Diabetes Care. 2012 Apr;35(4):873-8 – reference: 21876630 - World J Gastroenterol. 2011 Aug 7;17(29):3377-89 – reference: 20683947 - Hepatology. 2010 Aug;52(2):472-9 – reference: 17934148 - Diabetes Care. 2008 Jan;31(1):165-9 – reference: 21521847 - JAMA. 2011 Apr 27;305(16):1659-68 – reference: 25083079 - World J Gastroenterol. 2014 Jul 21;20(27):9055-71 – reference: 17327526 - JAMA. 2007 Feb 28;297(8):842-57 – reference: 23718573 - Aliment Pharmacol Ther. 2013 Jul;38(2):134-43 – reference: 23325287 - Eur J Gastroenterol Hepatol. 2013 Jun;25(6):652-8 – reference: 22173152 - J Hepatol. 2012 Apr;56(4):840-7 – reference: 23666091 - Nutrients. 2013 May 10;5(5):1544-60 – reference: 24731669 - Lancet Diabetes Endocrinol. 2014 Nov;2(11):901-10 – reference: 17090752 - Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E829-35 – reference: 21623852 - Aliment Pharmacol Ther. 2011 Aug;34(3):274-85 – reference: 25980762 - J Hepatol. 2015 Sep;63(3):705-12 – reference: 23973932 - J Hepatol. 2014 Jan;60(1):167-74 – reference: 22505194 - Hepatology. 2012 Sep;56(3):943-51 – reference: 16000931 - J Clin Gastroenterol. 2005 Aug;39(7):619-25 – reference: 25450705 - J Hepatol. 2015 Jan;62(1):15-7 – reference: 21748765 - Hepatology. 2011 Nov;54(5):1610-9 – reference: 23175136 - Hepatology. 2013 Apr;57(4):1357-65 – reference: 19625277 - Gut. 2009 Nov;58(11):1538-44 – reference: 19318102 - Gastroenterology. 2009 May;136(5):1490-2 – reference: 25011950 - Diabetes Care. 2014 Oct;37(10):2813-21 – reference: 25050550 - PLoS Med. 2014 Jul 22;11(7):e1001680 – reference: 25468160 - Lancet. 2015 Mar 14;385(9972):956-65 – reference: 25477264 - J Hepatol. 2015 May;62(5):1148-55 – reference: 25267322 - Aliment Pharmacol Ther. 2014 Nov;40(10):1155-70 – reference: 20063276 - Hepatology. 2010 Mar;51(3):828-35 – reference: 24818764 - Gastroenterology. 2014 Aug;147(2):377-84.e1 – reference: 24375711 - Hepatology. 2014 Jun;59(6):2188-95 – reference: 22871498 - J Hepatol. 2012 Dec;57(6):1312-8 – reference: 12198701 - Gastroenterology. 2002 Sep;123(3):745-50 – reference: 24076414 - Clin Gastroenterol Hepatol. 2014 Mar;12(3):394-402.e1 – reference: 23504926 - Hepatology. 2013 Oct;58(4):1287-95 – reference: 10644271 - Ann Intern Med. 2000 Jan 18;132(2):112-7 – reference: 24075754 - Atherosclerosis. 2013 Oct;230(2):258-67 – reference: 17391316 - Am J Gastroenterol. 2007 Jun;102(6):1251-8 – reference: 24679060 - N Engl J Med. 2014 May 22;370(21):2002-13 – reference: 25865049 - Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5 – reference: 20373368 - Hepatology. 2010 Apr;51(4):1209-17 – reference: 18718471 - Gastroenterology. 2008 Oct;135(4):1176-84 – reference: 12474149 - Liver Transpl. 2002 Dec;8(12):1114-22 – reference: 21051774 - BMJ. 2010 Nov 04;341:c5702 – reference: 22764020 - Am J Gastroenterol. 2012 Jul;107(7):976-8 – reference: 22467080 - Cancer Prev Res (Phila). 2012 Apr;5(4):544-52 – reference: 15629518 - J Hepatol. 2005 Jan;42(1):132-8 – reference: 19877169 - Hepatology. 2010 Feb;51(2):445-53 – reference: 20369224 - Diabetologia. 2010 Jul;53(7):1341-8 – reference: 23183525 - J Hepatol. 2013 May;58(5):1007-19 – reference: 24308774 - Aliment Pharmacol Ther. 2014 Feb;39(3):254-69 – reference: 18038452 - Hepatology. 2008 Feb;47(2):455-60 – reference: 19053049 - Hepatology. 2009 Jan;49(1):80-6 – reference: 20101745 - Hepatology. 2010 Feb;51(2):454-62 – reference: 24721975 - Heart. 2014 Jun;100(12):938-43 – reference: 22023985 - J Hepatol. 2012 Apr;56(4):944-51 – reference: 18436948 - BMJ. 2008 Apr 26;336(7650):924-6 – reference: 25917783 - Gastroenterology. 2015 Aug;149(2):379-88; quiz e15-6 – reference: 20427778 - N Engl J Med. 2010 May 6;362(18):1675-85 – reference: 22414768 - J Hepatol. 2012 Jul;57(1):157-66 – reference: 22418883 - Semin Liver Dis. 2012 Feb;32(1):3-13 – reference: 24206433 - Aliment Pharmacol Ther. 2014 Jan;39(1):3-14 – reference: 15277403 - Diabetes. 2004 Aug;53(8):2169-76 – reference: 20494470 - J Hepatol. 2010 Aug;53(2):372-84 – reference: 24345846 - J Pediatr Gastroenterol Nutr. 2014 May;58(5):632-6 – reference: 21180541 - Therap Adv Gastroenterol. 2009 May;2(3):157-63 – reference: 25482832 - Hepatology. 2015 Apr;61(4):1239-50 – reference: 22521357 - J Hepatol. 2012 Aug;57(2):384-91 – reference: 14999696 - Hepatology. 2004 Mar;39(3):770-8 – reference: 25557690 - Hepatology. 2015 Apr;61(4):1392-405 – reference: 21319198 - Hepatology. 2011 Mar;53(3):810-20 |
| SSID | ssj0061471 |
| Score | 2.4805295 |
| SecondaryResourceType | review_article |
| SourceID | doaj pubmedcentral proquest pubmed crossref karger |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 65 |
| SubjectTerms | Clinical Practice Guidelines |
| SummonAdditionalLinks | – databaseName: Karger Open Access Journals dbid: M-- link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB1BQYgLn4UGCjKIAxeLbOzEyXGhXThst5UAqbfIn7CiSqrtbiX-PTOJE7pVkbjkYDuOY4_9nu3xM8A7pOAmiCJwUZaO44BnuEGU5qQMjs2dhdR1LT1Xi0V5elqdxPUOOgvzi_yfO2nUUVsAAfdDt_EohJS34Q4CbtcFjzgfxlzEmH5qVdAZIITxqCG09Srp_pJ2TEaXVV8BoU6rHwGo__RNTPO6w-QVBJo9_P-yP4IHkWWyaW8Wj-GWb57AvaO4j_4U7OH065zj44Aexyyqg56xk3hoin3ekP4V-cQzpLUMaSL76ynD2sAWbcOn_f26S8tmer3-zebk5MEO-j2fXfg-O_z26QuP1y1wi7Unuc2CTX1hSO7G-zI3RVDBiMznDkchHBSLSmZppp2vTCGCNJaUcSbIEUxWWhXEM9hp2sbvAaOkXkijpc6kMaJUCicuRonSps5ULoH3Q_3XNmqR05UYZ3U3J8mreqy0BN6OSc97AY6bEn2kRhwTkGZ2F9CuftSxC9ZaGYl2WAqnJwjd3hg7cVIYV2mde6MT2O1bcMxmyHz_WvjxbNpH1ecuJPBmMJgauybtt-jGt5uLeqKIfaZyUiXwvDegMYvBEhNQW6a19QvbMc3yZyf_nSOFVVX14h_FfQn3kdTFZaJ92FmvNv4V3LWX6-XF6nXXbf4AdUcMtA priority: 102 providerName: Karger AG |
| Title | EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease |
| URI | https://karger.com/doi/10.1159/000443344 https://www.ncbi.nlm.nih.gov/pubmed/27055256 https://www.proquest.com/docview/1783920419 https://pubmed.ncbi.nlm.nih.gov/PMC5644799 https://doaj.org/article/a7b4b6183da1413ebbc1d43bd9aa5eba |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1662-4033 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061471 issn: 1662-4025 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVKGR databaseName: Karger Open Access Journals customDbUrl: eissn: 1662-4033 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061471 issn: 1662-4025 databaseCode: M-- dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.karger.com/OpenAccess providerName: Karger AG |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BhRAXxKPQ0FIZxIGL1SR2Yue40C4ctttKgLS3KOOHumqVrba7SPz7juNs6FaVuHDxwXGs2B7PfBOPvwH4RBAcvSg9F1pbTgoPOZKV5oEZnJY796ntVnqiplM9m1Xnd1J9hZiwSA8cJ-6oUSjpbS1sk5HCdYgms1KgrZqmcNhBI0I9G2cq6mCyOdHVKsOdIDLrPacQ2e6j7gxTCCm3LFFH2E9W6DLEXy8fgpv3oybvmKHxC3je40c2it_9Eh659hU8Pe1PyF-DORn9mHAqjkNxxnrezyt23l-HYt_WgdkqRLszAqyMACD7GwPDFp5NFy0fxcy5c8PGzWr1h01C-AY7jqc5u_BrfPLz63feJ1LghuZBcpN7k7oSA5GNc7rA0iuPIneFJf1C6q6sZJ7mjXUVlsJLNIHzJiPrj7k2yos3sNMuWrcHLDR1QmIjm1wiCq0UuSSohDapxcom8HkzqbXpWcZDsouruvM2iqoe5j-Bj0PT60it8VCjL2FlhgaBDburIBmpexmp_yUjCezGdR262XR-cK_-bDyKj-pr6xP4sJGCmjZdOElpWrdY39SZCrgylVmVwNsoFUMXeeAnIiCZgNqSl60hbD9p5xcdsXdB4FRV1bv_MeZ9eEbYrv9bdAA7q-XavYcn5vdqfrM8hMdqpg-7PUPlKee3H74YUQ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB1BQZQLnwUCBQziwMUiiZ04Pi60SxHZbSWK1FtkOzasWiXVdheJf884cUK3KhKXHGzHcTxjz7Nn_AzwDiG4dix3lBVFTXHC01SjlaaeGRzFnbq47iRdivm8ODmRR2G_w5-FOfXxzx016sgtgAb3Q-d4ZIzzm3BLyCz1ujyjdJhz0cb0S6vcnwFCMx44hDZe9by_njsm9ZdVXzJCHVc_GqD-09chzasBk5cs0PT-_7f9AdwLKJNMerV4CDds8wjuzIIf_TGY_cm3kuJjzz8OSWAHPSNH4dAU-bz2_Fc-Jp4grCUIE8nfSBnSOjJvGzrp79ddGDJVq9VvUvogD7LX-3x24Pt0__jTAQ3XLVCDvcepSZ2Jba493Y21RaZzJ5xmqc1qnIVwUswlT-NU1VbqnDmujWfGSRAj6LQwwrEnsNW0jX0GxBe1jGvFVcq1ZoUQuHDRghUmrrWsI3g_9H9lAhe5vxLjrOrWJJmsxk6L4O1Y9Lwn4Liu0EcvxLGA58zuEtrljyoMwUoJzVEPC1arBE231dokNWe6lkplVqsIdnoJjtUMle9eST-cTvqs6rx2EbwZFKbCoen9Laqx7fqiSoRHnzFPZARPewUaqxg0MQKxoVobv7CZ0yx-dvTfGUJYIeXzfzT3NWwfHM_Kqvwy__oC7iLAC1tGu7C1Wq7tS7htfq0WF8tX3RD6A1ufD60 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EASL-EASD-EASO+Clinical+Practice+Guidelines+for+the+Management+of+Non-Alcoholic+Fatty+Liver+Disease&rft.jtitle=Obesity+facts&rft.date=2016&rft.issn=1662-4025&rft.eissn=1662-4033&rft.volume=9&rft.issue=2&rft.spage=65&rft.epage=90&rft_id=info:doi/10.1159%2F000443344&rft.externalDBID=n%2Fa&rft.externalDocID=10_1159_000443344 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1662-4025&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1662-4025&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1662-4025&client=summon |